Aptamers News and Research RSS Feed - Aptamers News and Research

UC researcher awarded NCI grant to study effect of MED1 protein on HER2-positive breast cancer

UC researcher awarded NCI grant to study effect of MED1 protein on HER2-positive breast cancer

Xiaoting Zhang, PhD, associate professor in the Department of Cancer Biology at the University of Cincinnati College of Medicine, has received a $1.8 million, five-year, R01 award (R01CA197865) from the National Cancer Institute to continue breast cancer research focusing on the function of the protein MED1 on HER2-positive breast cancer. [More]
Magnetizing biomolecules: an interview with Dr. Fred Whipple, AMSBIO

Magnetizing biomolecules: an interview with Dr. Fred Whipple, AMSBIO

Nanoparticle technology was originally developed in the 1980s and 1990s. As the technology evolved, it soon became possible to produce uniform nanoscopic beads that are magnetic, and that also have a variety of specific surface chemistries. It was immediately evident that such beads could be used to great advantage for biochemical separations. [More]
New light-triggered strategy can provide accurate control over aptamer-based therapeutics

New light-triggered strategy can provide accurate control over aptamer-based therapeutics

While aptamers—single-stranded nucleic acids—offer promise as drug-delivery tools for cancer treatment, it has proven difficult to get them to tumor cells at therapeutic levels. [More]
AMSBIO introduces revolutionary magnetic technology for bioseparations

AMSBIO introduces revolutionary magnetic technology for bioseparations

AMSBIO announces MagSi-Direct - a revolutionary technology that brings the power, simplicity, and convenience of magnetic separation to researchers involved in cell biology, protein chemistry, flow cytometry, diagnostics development and many other fields. [More]
Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA. [More]
Researchers find new technique to detect just a handful of lurking tumor cells

Researchers find new technique to detect just a handful of lurking tumor cells

Beating cancer is all about early detection, and new research from the University of South Carolina is another step forward in catching the disease early. A team of chemists is reporting a new way to detect just a handful of lurking tumor cells, which can be outnumbered a billion to one in the bloodstream by healthy cells. [More]
Aptamer kits for cell isolation and flow cytometry introduced by AMSBIO

Aptamer kits for cell isolation and flow cytometry introduced by AMSBIO

AMSBIO has announced the introduction of new aptamer kits for cell isolation and flow cytometry. Aptamers are oligonucleotides or peptides that bind to a specific target molecule. Aptamers are useful in biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of the commonly used biomolecule, antibodies. [More]
NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013. [More]
Chemists develop new method for parallel protein analysis

Chemists develop new method for parallel protein analysis

Chemists at Johannes Gutenberg University Mainz (JGU) have developed a new method for parallel protein analysis that is, in principle, capable of identifying hundreds or even thousands of different proteins. It could be used to detect the presence of viruses and identify their type in tiny samples. At the same time, it is very cost-effective and quick. [More]
NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease. [More]
Researchers develop RNA aptamers that inhibit HCV replication

Researchers develop RNA aptamers that inhibit HCV replication

Treatments against hepatitis C virus have only been partially successful. A major problem is that antivirals generate drug resistance. Now Seong-Wook Lee of Dankook University, Yongin, Republic of Korea and his collaborators have developed agents that bind to the business end of a critical protein, disabling it so successfully that no resistance has arisen. [More]
New range of Aptamer Protein Precipitation Kits announced by AMSBIO

New range of Aptamer Protein Precipitation Kits announced by AMSBIO

AMSBIO has announced a new range of Aptamer Protein Precipitation Kits that bind with unmatched high specificity and affinity to target molecules. [More]
Experimental drug can reduce breast-cancer aggressiveness, restore drug-sensitivity

Experimental drug can reduce breast-cancer aggressiveness, restore drug-sensitivity

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggests that an unusual experimental drug can reduce breast-cancer aggressiveness, reverse resistance to the drug fulvestrant and perhaps improve the effectiveness of other breast-cancer drugs. [More]
New apatamer can boost therapeutic effect of cell-based vaccines

New apatamer can boost therapeutic effect of cell-based vaccines

A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. [More]
TU Darmstadt’s biosensor can diagnose African sleeping sickness before it breaks out

TU Darmstadt’s biosensor can diagnose African sleeping sickness before it breaks out

African sleeping sickness is an infectious disease that is widespread south of the Sahara Desert. Although the around sixty million people residing in tropical Africa run the risk of becoming infected with the disease every day, only around four million of them are monitored for the disease by disease-control authorities. [More]
BioResearch Open Access explores Cell-SELEX technology

BioResearch Open Access explores Cell-SELEX technology

SELEX is a rapid, efficient, and iterative high-throughput method for screening large libraries of molecules to identify those with the potential to be developed as drug compounds or research tools. Advances in SELEX technology that have enabled screening in live cells, called Cell-SELEX, are explored in a comprehensive Review article published in BioResearch Open Access, a bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc. [More]
Researchers use DNA molecules to stimulate repair of nerve coatings that mimic MS

Researchers use DNA molecules to stimulate repair of nerve coatings that mimic MS

Mayo Clinic researchers have successfully used smaller, folded DNA molecules to stimulate regeneration and repair of nerve coatings in mice that mimic multiple sclerosis (MS). They say the finding, published today in the journal PLoS ONE, suggests new possible therapies for MS patients. [More]

NEC, SomaLogic release professional software tool

SomaLogic, Inc., and NEC Corporation today announced the release of SomaSuite, a professional software tool developed by NEC that provides simple, reliable and direct access to the highly multiplexed proteomic data generated by SomaLogic's SOMAscan proteomics assay technology. [More]

SomaLogic, HUNT Biosciences partner to advance clinical use of cardiovascular biomarkers

HUNT Biosciences and SomaLogic, Inc., today announced a new collaboration to advance the clinical use of protein biomarkers, with an initial focus on the validation of biomarkers for the prediction of cardiovascular events such as strokes, heart attacks, and heart failure. [More]
Gold nanostars can deliver drug directly to cancer cell nucleus

Gold nanostars can deliver drug directly to cancer cell nucleus

Nanotechnology offers powerful new possibilities for targeted cancer therapies, but the design challenges are many. Northwestern University scientists now are the first to develop a simple but specialized nanoparticle that can deliver a drug directly to a cancer cell's nucleus -- an important feature for effective treatment. [More]
Advertisement
Advertisement